NIH R01 · 2025
Few viable treatments exist for patients with locally advanced or metastatic well-differentiated or dedifferentiated liposarcoma (WD/DDLS), which are rare and often neglected orphan cancers. There are approximately 1000 patients per year in the US diagnosed with WD/DDLS, and these cancers generally do not respond to chemotherapy. Recent trials of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, motivated by the finding that the CDK4 gene is amplified in >90% of WD/DDLS, show these agents stabilize disease that had been growing prior to treatment and demonstrated clinically meaningful median progression-free survival (PFS) of 66% at 12 weeks but responses were uncommon. To enhance response…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.